• ACLU blasts Michigan prosecutors for bioterrorism charge against HIV-positive man

    Prosecutors in Michigan are charging an HIV-positive man with violating the state’s bioterrorism law for biting his neighbors during an altercation; the ACLU claims the statute behind the state’s bioterrorism law was not intended to cover an HIV-person biting another person; prosecutors charged the man with assault and later added a bioterrorism charge on claims he was trying to use the virus as a weapon

  • Synthesized polymer neutralizes both biological and chemical weapons

    Biological tissues to respond rapidly and appropriately to changing environments; this logic was applied by University of Pittsburgh researchers: they have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins

  • Experts: Weak biosafety laws in Africa an invitation to bioterrorists

    To feed the growing number of people on the African continent, food production on the continent must be increased by up to 300 percent by 2050, and scientists say the only way to do so is by using biotechnology; many are worried that weak or nonexistent biosafety laws in Africa would make it easy for bioterrorists to exploit increased biotechnology activity for their nefarious purposes

  • How best to protect first responders from anthrax

    The first responders who rushed to Senator Tom Daschle’s office on 15 October 2001 were protected by personal protective equipment (PPE); yet, nasal swabs taken from them after they got out of the building revealed that some had been exposed to anthrax; experts argue that first responders and emergency personnel should all be vaccinated

  • Two New York labs to develop anti-botulism drugs

    U.S. Department of Energy’s Brookhaven National Laboratory and Stony Brook University’s Institute of Chemical Biology and Drug Discovery to receive $1.4 million in Department of Defense research funds to develop anti-botulism drugs

  • PharmAthene says its anthrax vaccine is superior to first-generation vaccine

    PharmAthene’s anthrax vaccine, called SparVax, will require three doses over a 60-day period — the first-generation vaccine requires five doses over 18 months; a course of treatment with the currently available vaccine costs about $125; SparVax would cost just $45 a treatment

  • $150 million anthrax vaccine contract goes to firm with close Democratic Party ties

    The Department of Health and Human Services (HHS) announced on the evening of 29 December that it was awarding PharmAthene $150 million to develop and produce an anthrax vaccine; FOXNews notes the strong ties to the Democratic Party of senior company executives

  • Europe would be better with a generic, rather than disease-specific, pandemic response plan

    New study argues that the emphasis in Europe on disease-specific emergency plans utilized by most European countries could cost precious time and resources; “Countries and organizations invest enormous resources in developing plans for specific diseases, which may not even present a threat in the future,” the study says

  • U.S. anthrax response undermined by public ignorance, lack of confidence in government

    A Harvard School of Public Health’s survey found that nearly 40 percent of respondents who said they would likely accept antibiotic pills distributed from public health authorities after an anthrax attack also said they would not start taking them immediately; about 35 percent indicated they would hold onto the drugs until they knew for certain they had been exposed to anthrax

  • Immunovaccine offers enhanced anthrax vaccine candidate

    Currently, to provide protection from anthrax, individuals receive a 6-dose regime with three injections given two weeks apart, followed by three additional injections given at 6, 12, and 18 months; annual booster injections of the vaccine are recommended thereafter; Canadian company Immunovaccine says it developed a method to cut this arduous regimen by half

  • Tulane University, Corgenix awarded $15,000,000 to expand Lassa fever research

    Lassa fever, because of its high fatality rate, the ability to spread easily by human-to-human contact, and the potential for aerosol release, is classified as a bio safety level 4 agent and is included on the NIAID Category A list of potential bioterrorism threats; new study will focus on identification of novel B-cell epitopes on Lassa virus proteins, aiming to develop agents to treat and prevent the disease

  • New virtual community to connect bioterrorism experts

    Mount St. Mary’s University launches launched a new virtual community that allows intelligence officers, students, and even Capitol Hill executives to network with bioterrorism experts and academics; the invitation-only network takes place on the Yakabox knowledge sharing systems which are certified for use in classified environments by the U.S. government

  • U.S. gets “F” in preparation for threat of biological terrorism

    The Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism gave the U.S. government an “F” for bioweapon preparedness; the commission warned: “On the current course, what is likely to occur within a very few years is an attack using weapons of mass destruction — probably a bioweapon — that will fundamentally change the character of life for the world’s democracies”

  • Battling against biological threats with ultrasonics

    A tweezers-like device uses ultrasonics to detect bioterror agents; when a small sample such as a powdery anthrax mix is placed inside the device, an array of piezoelectric transducers would generate an ultrasonic force field onto the sample; security officials would be able to detect anthrax from innocuous powders in the mix through differences in compressibility and density

  • Recalled beef in California could be two years old

    An examination of tainted beef sold to restaurants and stores by a California company between 5 and 15 January this year revealed that it was processed nearly two years old; this means that beef already in the freezers of restaurants, hotels, stores, and consumers may be tainted with E. coli